Table of contents
The marketing authorisation for Kogenate Bayer has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Kogenate Bayer : EPAR - Summary for the public (PDF/637.91 KB)
First published: 12/05/2009
Last updated: 04/05/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
16/11/2017 Kogenate Bayer - EMEA/H/C/000275 - A31/0185
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).
This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes15/09/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 December 201320/12/2013
PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients06/12/2013